FOLR1 and ovarian carcinoma: In addition, in the phase I STRO-002-GM2 study (NCT05200364) it is being tested in combination with bevacizumab in patients with recurrent high-grade epithelial ovarian cancer, while in the phase II/III REFRaME-01 study (NCT05870748) it is being compared with the treatment of choice in patients with recurrent platinum-resistant disease expressing FRα [107,108].